Q-omics provides the consensus-scored B9D2 profile across patient tissues and cancer cell-line models. B9D2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, B9D2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, B9D2 RNA expression shows 19,668 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where B9D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B9D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B9D2 survival associations across molecular data types. B9D2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B9D2 RNA expression–survival associations across cancer types. High B9D2 expression shows unfavorable associations in UVM, LGG, LUAD and LIHC, but favorable associations in BLCA and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for B9D2 RNA expression.
This table summarizes B9D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for B9D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B9D2 shows lower tumor expression in KICH, THCA, LUAD and LUSC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher B9D2 RNA expression in tumor versus normal tissue (log2 FC = +1.122, t-test p < 0.001).
This table shows molecular features associated with B9D2 in patient tissues and cancer cell lines. In patient samples, B9D2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, B9D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
